Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C32H40BrN5O5 |
Molecular Weight | 654.5952 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 6 / 6 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CC(C)C[C@@]1([H])C(=O)N2CCC[C@@]2([H])[C@]3(N1C(=O)[C@](C(C)C)(N=C([C@]4([H])C=C5c6cccc7c6c(C[C@@]5([H])N(C)C4)c(Br)[nH]7)O)O3)O
InChI
InChIKey=OZVBMTJYIDMWIL-AYFBDAFISA-N
InChI=1S/C32H40BrN5O5/c1-16(2)12-24-29(40)37-11-7-10-25(37)32(42)38(24)30(41)31(43-32,17(3)4)35-28(39)18-13-20-19-8-6-9-22-26(19)21(27(33)34-22)14-23(20)36(5)15-18/h6,8-9,13,16-18,23-25,34,42H,7,10-12,14-15H2,1-5H3,(H,35,39)/t18-,23-,24+,25+,31-,32+/m1/s1
DescriptionCurator's Comment:: description was created based on several sources, including:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/020866lbl.pdf | https://www.drugs.com/mtm/bromocriptine.html
Curator's Comment:: description was created based on several sources, including:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/020866lbl.pdf | https://www.drugs.com/mtm/bromocriptine.html
Bromocriptine is an ergot derivative with potent dopamine receptor agonist activity, which activates post-synaptic dopamine receptors. Bromocriptine is indicated for the treatment of dysfunctions associated with hyperprolactinemia. Bromocriptine therapy is indicated in the treatment of acromegaly and in the treatment of the signs and symptoms of idiopathic or postencephalitic Parkinson’s disease. It is approved as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. Some commonly reported adverse reactions include nausea, fatigue, dizziness, vomiting and headache. Bromocriptine may interact with dopamine antagonists, butyrophenones and certain other agents.
CNS Activity
Originator
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL217 Sources: https://www.ncbi.nlm.nih.gov/pubmed/8787038 |
36.0 nM [Ki] | ||
Target ID: CHEMBL234 Sources: https://www.ncbi.nlm.nih.gov/pubmed/8787038 |
197.0 nM [Ki] | ||
Target ID: CHEMBL2056 Sources: https://www.ncbi.nlm.nih.gov/pubmed/8787038 |
2.2 µM [Ki] | ||
Target ID: CHEMBL2093864 Sources: https://www.ncbi.nlm.nih.gov/pubmed/20138024 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Palliative | PARLODEL Approved UseHyperprolactinemia-Associated Dysfunctions Bromocriptine mesylate tablets are indicated for the treatment of dysfunctions associated with hyperprolactinemia including amenorrhea with or without galactorrhea, infertility or hypogonadism. Bromocriptine mesylate tablets treatment is indicated in patients with prolactin-secreting adenomas, which may be the basic underlying endocrinopathy contributing to the above clinical presentations. Reduction in tumor size has been demonstrated in both male and female patients with macroadenomas. In cases where adenectomy is elected, a course of bromocriptine mesylate tablets therapy may be used to reduce the tumor mass prior to surgery. Acromegaly Bromocriptine mesylate tablets therapy is indicated in the treatment of acromegaly. Bromocriptine mesylate tablets therapy, alone or as adjunctive therapy with pituitary irradiation or surgery, reduces serum growth hormone by 50% or more in approximately ½ of patients treated, although not usually to normal levels. Since the effects of external pituitary radiation may not become maximal for several years, adjunctive therapy with bromocriptine mesylate tablets offers potential benefit before the effects of irradiation are manifested. Parkinson's Disease Bromocriptine mesylate tablets are indicated in the treatment of the signs and symptoms of idiopathic or postencephalitic Parkinson's disease. As adjunctive treatment to levodopa (alone or with a peripheral decarboxylase inhibitor), bromocriptine mesylate tablets therapy may provide additional therapeutic benefits in those patients who are currently maintained on optimal dosages of levodopa, those who are beginning to deteriorate (develop tolerance) to levodopa therapy, and those who are experiencing end of dose failure on levodopa therapy. Bromocriptine mesylate tablets therapy may permit a reduction of the maintenance dose of levodopa and, thus may ameliorate the occurrence and/or severity of adverse reactions associated with long-term levodopa therapy such as abnormal involuntary movements (e.g., dyskinesias) and the marked swings in motor function (on-off phenomenon). Continued efficacy of bromocriptine mesylate tablets therapy during treatment of more than 2 years has not been established. Data are insufficient to evaluate potential benefit from treating newly diagnosed Parkinson's disease with bromocriptine mesylate tablets. Studies have shown, however, significantly more adverse reactions (notably nausea, hallucinations, confusion and hypotension) in bromocriptine mesylate treated patients than in levodopa/carbidopa treated patients. Patients unresponsive to levodopa are poor candidates for bromocriptine mesylate tablets therapy. Launch Date2.67839996E11 |
|||
Primary | PARLODEL Approved UseHyperprolactinemia-Associated Dysfunctions Bromocriptine mesylate tablets are indicated for the treatment of dysfunctions associated with hyperprolactinemia including amenorrhea with or without galactorrhea, infertility or hypogonadism. Bromocriptine mesylate tablets treatment is indicated in patients with prolactin-secreting adenomas, which may be the basic underlying endocrinopathy contributing to the above clinical presentations. Reduction in tumor size has been demonstrated in both male and female patients with macroadenomas. In cases where adenectomy is elected, a course of bromocriptine mesylate tablets therapy may be used to reduce the tumor mass prior to surgery. Acromegaly Bromocriptine mesylate tablets therapy is indicated in the treatment of acromegaly. Bromocriptine mesylate tablets therapy, alone or as adjunctive therapy with pituitary irradiation or surgery, reduces serum growth hormone by 50% or more in approximately ½ of patients treated, although not usually to normal levels. Since the effects of external pituitary radiation may not become maximal for several years, adjunctive therapy with bromocriptine mesylate tablets offers potential benefit before the effects of irradiation are manifested. Parkinson's Disease Bromocriptine mesylate tablets are indicated in the treatment of the signs and symptoms of idiopathic or postencephalitic Parkinson's disease. As adjunctive treatment to levodopa (alone or with a peripheral decarboxylase inhibitor), bromocriptine mesylate tablets therapy may provide additional therapeutic benefits in those patients who are currently maintained on optimal dosages of levodopa, those who are beginning to deteriorate (develop tolerance) to levodopa therapy, and those who are experiencing end of dose failure on levodopa therapy. Bromocriptine mesylate tablets therapy may permit a reduction of the maintenance dose of levodopa and, thus may ameliorate the occurrence and/or severity of adverse reactions associated with long-term levodopa therapy such as abnormal involuntary movements (e.g., dyskinesias) and the marked swings in motor function (on-off phenomenon). Continued efficacy of bromocriptine mesylate tablets therapy during treatment of more than 2 years has not been established. Data are insufficient to evaluate potential benefit from treating newly diagnosed Parkinson's disease with bromocriptine mesylate tablets. Studies have shown, however, significantly more adverse reactions (notably nausea, hallucinations, confusion and hypotension) in bromocriptine mesylate treated patients than in levodopa/carbidopa treated patients. Patients unresponsive to levodopa are poor candidates for bromocriptine mesylate tablets therapy. Launch Date2.67839996E11 |
|||
Primary | PARLODEL Approved UseHyperprolactinemia-Associated Dysfunctions Bromocriptine mesylate tablets are indicated for the treatment of dysfunctions associated with hyperprolactinemia including amenorrhea with or without galactorrhea, infertility or hypogonadism. Bromocriptine mesylate tablets treatment is indicated in patients with prolactin-secreting adenomas, which may be the basic underlying endocrinopathy contributing to the above clinical presentations. Reduction in tumor size has been demonstrated in both male and female patients with macroadenomas. In cases where adenectomy is elected, a course of bromocriptine mesylate tablets therapy may be used to reduce the tumor mass prior to surgery. Acromegaly Bromocriptine mesylate tablets therapy is indicated in the treatment of acromegaly. Bromocriptine mesylate tablets therapy, alone or as adjunctive therapy with pituitary irradiation or surgery, reduces serum growth hormone by 50% or more in approximately ½ of patients treated, although not usually to normal levels. Since the effects of external pituitary radiation may not become maximal for several years, adjunctive therapy with bromocriptine mesylate tablets offers potential benefit before the effects of irradiation are manifested. Parkinson's Disease Bromocriptine mesylate tablets are indicated in the treatment of the signs and symptoms of idiopathic or postencephalitic Parkinson's disease. As adjunctive treatment to levodopa (alone or with a peripheral decarboxylase inhibitor), bromocriptine mesylate tablets therapy may provide additional therapeutic benefits in those patients who are currently maintained on optimal dosages of levodopa, those who are beginning to deteriorate (develop tolerance) to levodopa therapy, and those who are experiencing end of dose failure on levodopa therapy. Bromocriptine mesylate tablets therapy may permit a reduction of the maintenance dose of levodopa and, thus may ameliorate the occurrence and/or severity of adverse reactions associated with long-term levodopa therapy such as abnormal involuntary movements (e.g., dyskinesias) and the marked swings in motor function (on-off phenomenon). Continued efficacy of bromocriptine mesylate tablets therapy during treatment of more than 2 years has not been established. Data are insufficient to evaluate potential benefit from treating newly diagnosed Parkinson's disease with bromocriptine mesylate tablets. Studies have shown, however, significantly more adverse reactions (notably nausea, hallucinations, confusion and hypotension) in bromocriptine mesylate treated patients than in levodopa/carbidopa treated patients. Patients unresponsive to levodopa are poor candidates for bromocriptine mesylate tablets therapy. Launch Date2.67839996E11 |
|||
Primary | CYCLOSET Approved UseDrug is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. Launch Date1.24139523E12 |
Cmax
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
628 pg/mL |
5 mg 1 times / day steady-state, oral dose: 5 mg route of administration: Oral experiment type: STEADY-STATE co-administered: |
BROMOCRIPTINE plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
AUC
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
2377 pg × h/mL |
5 mg 1 times / day steady-state, oral dose: 5 mg route of administration: Oral experiment type: STEADY-STATE co-administered: |
BROMOCRIPTINE plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
T1/2
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
4.85 h |
5 mg 1 times / day steady-state, oral dose: 5 mg route of administration: Oral experiment type: STEADY-STATE co-administered: |
BROMOCRIPTINE plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
Funbound
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
4% |
5 mg 1 times / day steady-state, oral dose: 5 mg route of administration: Oral experiment type: STEADY-STATE co-administered: |
BROMOCRIPTINE plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
Doses
Dose | Population | Adverse events |
---|---|---|
4.8 mg 1 times / day multiple, oral (max) Recommended Dose: 4.8 mg, 1 times / day Route: oral Route: multiple Dose: 4.8 mg, 1 times / day Sources: Page: p.3 |
unhealthy, 27-80 n = 3070 Health Status: unhealthy Condition: Type 2 diabetes mellitus Age Group: 27-80 Sex: M+F Population Size: 3070 Sources: Page: p.3 |
Disc. AE: Nausea... AEs leading to discontinuation/dose reduction: Nausea Sources: Page: p.3 |
4.8 mg 1 times / day multiple, oral MTD Dose: 4.8 mg, 1 times / day Route: oral Route: multiple Dose: 4.8 mg, 1 times / day Sources: Page: p.1691, 1699 |
unhealthy, 55+/-1 n = 314 Health Status: unhealthy Condition: Type 2 diabetes mellitus Age Group: 55+/-1 Sex: M+F Population Size: 314 Sources: Page: p.1691, 1699 |
Disc. AE: Nausea, Dizziness... AEs leading to discontinuation/dose reduction: Nausea (4%) Sources: Page: p.1691, 1699Dizziness (2.8%) Asthenia (1.5%) Rhinitis (1.5%) |
4.8 mg 1 times / day multiple, oral MTD Dose: 4.8 mg, 1 times / day Route: oral Route: multiple Dose: 4.8 mg, 1 times / day Sources: Page: p.1505, 1507 |
unhealthy, 59.5 +/- 10.2 n = 2054 Health Status: unhealthy Condition: Type 2 diabetes mellitus Age Group: 59.5 +/- 10.2 Sex: M+F Population Size: 2054 Sources: Page: p.1505, 1507 |
Disc. AE: Nausea... AEs leading to discontinuation/dose reduction: Nausea Sources: Page: p.1505, 1507 |
100 mg 1 times / day multiple, oral Highest studied dose Dose: 100 mg, 1 times / day Route: oral Route: multiple Dose: 100 mg, 1 times / day Sources: |
unhealthy Health Status: unhealthy Condition: Parkinson's Disease Sources: |
|
300 mg single, oral Highest studied dose Dose: 300 mg Route: oral Route: single Dose: 300 mg Sources: Page: p.978 |
unhealthy n = 1 Health Status: unhealthy Condition: Parkinson's Disease Population Size: 1 Sources: Page: p.978 |
|
30 mg 1 times / day multiple, oral (total) Recommended Dose: 30 mg, 1 times / day Route: oral Route: multiple Dose: 30 mg, 1 times / day Sources: |
unhealthy Health Status: unhealthy Condition: Prolactinomas|Hypogonadism|Galactorrhea syndromes|Infertility Sources: |
AEs
AE | Significance | Dose | Population |
---|---|---|---|
Nausea | Disc. AE | 4.8 mg 1 times / day multiple, oral (max) Recommended Dose: 4.8 mg, 1 times / day Route: oral Route: multiple Dose: 4.8 mg, 1 times / day Sources: Page: p.3 |
unhealthy, 27-80 n = 3070 Health Status: unhealthy Condition: Type 2 diabetes mellitus Age Group: 27-80 Sex: M+F Population Size: 3070 Sources: Page: p.3 |
Asthenia | 1.5% Disc. AE |
4.8 mg 1 times / day multiple, oral MTD Dose: 4.8 mg, 1 times / day Route: oral Route: multiple Dose: 4.8 mg, 1 times / day Sources: Page: p.1691, 1699 |
unhealthy, 55+/-1 n = 314 Health Status: unhealthy Condition: Type 2 diabetes mellitus Age Group: 55+/-1 Sex: M+F Population Size: 314 Sources: Page: p.1691, 1699 |
Rhinitis | 1.5% Disc. AE |
4.8 mg 1 times / day multiple, oral MTD Dose: 4.8 mg, 1 times / day Route: oral Route: multiple Dose: 4.8 mg, 1 times / day Sources: Page: p.1691, 1699 |
unhealthy, 55+/-1 n = 314 Health Status: unhealthy Condition: Type 2 diabetes mellitus Age Group: 55+/-1 Sex: M+F Population Size: 314 Sources: Page: p.1691, 1699 |
Dizziness | 2.8% Disc. AE |
4.8 mg 1 times / day multiple, oral MTD Dose: 4.8 mg, 1 times / day Route: oral Route: multiple Dose: 4.8 mg, 1 times / day Sources: Page: p.1691, 1699 |
unhealthy, 55+/-1 n = 314 Health Status: unhealthy Condition: Type 2 diabetes mellitus Age Group: 55+/-1 Sex: M+F Population Size: 314 Sources: Page: p.1691, 1699 |
Nausea | 4% Disc. AE |
4.8 mg 1 times / day multiple, oral MTD Dose: 4.8 mg, 1 times / day Route: oral Route: multiple Dose: 4.8 mg, 1 times / day Sources: Page: p.1691, 1699 |
unhealthy, 55+/-1 n = 314 Health Status: unhealthy Condition: Type 2 diabetes mellitus Age Group: 55+/-1 Sex: M+F Population Size: 314 Sources: Page: p.1691, 1699 |
Nausea | Disc. AE | 4.8 mg 1 times / day multiple, oral MTD Dose: 4.8 mg, 1 times / day Route: oral Route: multiple Dose: 4.8 mg, 1 times / day Sources: Page: p.1505, 1507 |
unhealthy, 59.5 +/- 10.2 n = 2054 Health Status: unhealthy Condition: Type 2 diabetes mellitus Age Group: 59.5 +/- 10.2 Sex: M+F Population Size: 2054 Sources: Page: p.1505, 1507 |
Overview
CYP3A4 | CYP2C9 | CYP2D6 | hERG |
---|---|---|---|
Drug as perpetrator
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
yes [IC50 1.69 uM] | ||||
yes [Ki 6.52 uM] | ||||
Sources: https://pubmed.ncbi.nlm.nih.gov/9111066/ |
yes |
Drug as victim
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
Page: 3.0 |
inconclusive | |||
likely | ||||
likely | ||||
likely | ||||
Page: 3.0 |
yes | |||
Page: 26.0 |
yes | |||
yes | ||||
yes | ||||
yes |
PubMed
Title | Date | PubMed |
---|---|---|
Cardiovascular responses to intrathecal dopamine receptor agonists in conscious DOCA-salt hypertensive rats. | 1999 |
|
Actions of adenosine A2A receptor antagonist KW-6002 on drug-induced catalepsy and hypokinesia caused by reserpine or MPTP. | 1999 Nov |
|
[The treatment of cyclic mastalgia--a comparative study between the preparations Bromocriptine and Geritamin]. | 2000 |
|
Sleep attacks and Parkinson's disease treatment. | 2000 Apr 15 |
|
Use of the dopamine agonists bromocriptine and cabergoline in the management of risperidone-induced hyperprolactinemia in patients with psychotic disorders. | 2000 Dec |
|
[Dopaminergic agonists in the treatment of Parkinson's disease]. | 2000 Dec |
|
Inhibitory effect of human immunodeficiency virus protease inhibitors on multidrug resistance transporter P-glycoproteins. | 2000 Dec |
|
Clinical pharmacology of dopamine agonists. | 2000 Jan |
|
Role of dopamine D3 receptors in thermoregulation: a reappraisal. | 2000 Jan 17 |
|
Neuroleptic malignant syndrome after venlafaxine. | 2000 Jan 22 |
|
Clinical features and medical treatment of male prolactinomas. | 2001 |
|
Cabergoline versus bromocriptine for levodopa-induced complications in Parkinson's disease. | 2001 |
|
Dopamine D2 receptor gene expression in human adenohypophysial adenomas. | 2001 Apr |
|
Mechanisms of inverse agonism of antipsychotic drugs at the D(2) dopamine receptor: use of a mutant D(2) dopamine receptor that adopts the activated conformation. | 2001 Apr |
|
In vivo and in vitro effects of prolactin and growth hormone on lipid metabolism in a teleost, Anabas testudineus (Bloch). | 2001 Apr |
|
Polysomnographic measures in Parkinson's disease: a comparison between patients with and without REM sleep disturbances. | 2001 Apr 17 |
|
Neostriatal muscarinic receptor subtypes involved in the generation of tremulous jaw movements in rodents implications for cholinergic involvement in parkinsonism. | 2001 Apr 27 |
|
Effects of dopamine d2 receptor agonists in a pituitary transplantation-induced hyperprolactinaemia/anovulation model in rats. | 2001 Aug |
|
Luteolytic effect of prolactin is dependent on the degree of differentiation of luteal cells in the rat. | 2001 Aug |
|
Upregulation of lymphocyte apoptosis as a strategy for preventing and treating autoimmune disorders: a role for whole-food vegan diets, fish oil and dopamine agonists. | 2001 Aug |
|
Bromocriptine-induced dissociation of hyperglycemia and prolactin response to restraint. | 2001 Feb |
|
Pituitary adenomas in childhood and adolescence. Clinical analysis of 10 cases. | 2001 Feb |
|
[Decreased tumor size in hypophyseal macroadenoma--empty sella syndrome]. | 2001 Feb 15 |
|
Mechanisms for suckling-induced changes in expression of prolactin receptor in the hypothalamus of the lactating rat. | 2001 Feb 9 |
|
Maternal prolactin secretion during labor. The role of dopamine. | 2001 Jan |
|
Characterization of acute inhibition of Na/H exchanger NHE-3 by dopamine in opossum kidney cells. | 2001 Jan |
|
Pharmacology of [3H]R(+)-7-OH-DPAT binding in the rat caudate-putamen. | 2001 Jan |
|
Hepatic Encephalopathy. | 2001 Jul |
|
Centrally mediated effects of bromocriptine on cardiac sympathovagal balance. | 2001 Jul |
|
Rehabilitative management of post-stroke visuospatial inattention. | 2001 Jul 10 |
|
Microvessel density in pituitary adenomas and carcinomas. | 2001 Jun |
|
Effect of serotonin depletion by p-chlorophenylalanine on serum prolactin levels in estrogen-treated ovariectomized rats: insights concerning the serotoninergic, dopaminergic and opioid systems. | 2001 Jun |
|
[Pharmacological effects of cabergoline against parkinsonism]. | 2001 Jun |
|
Neuroleptic malignant syndrome during a change from haloperidol to risperidone. | 2001 Jun |
|
Estrogen, prolactin, and autoimmunity: actions and interactions. | 2001 Jun |
|
Cerebrospinal fluid fistula as the presenting manifestation of pituitary adenoma: case report with a 4-year follow-up. | 2001 Jun |
|
The effect of prolactin and bromocriptine on human peripheral immune status. | 2001 Mar |
|
Positive outcomes in traumatic brain injury-vegetative state: patients treated with bromocriptine. | 2001 Mar |
|
Effects of chronic bromocriptine treatment on tyrosine hydroxylase (TH) mRNA expression, TH activity and median eminence dopamine concentrations in ageing rats. | 2001 Mar |
|
[Parkinson disease: diagnostic and therapeutic criteria]. | 2001 Mar 3 |
|
Haloperidol-stomach lesions attenuation by pentadecapeptide BPC 157, omeprazole, bromocriptine, but not atropine, lansoprazole, pantoprazole, ranitidine, cimetidine and misoprostol in mice. | 2001 Mar 9 |
|
Central bromocriptine-induced tachycardia is reversed to bradycardia in conscious, deoxycorticosterone acetate-salt hypertensive rats. | 2001 May |
|
Cannabinoid CB(1) receptor agonists produce cerebellar dysfunction in mice. | 2001 May |
|
Fertile estrus induced in bitches by bromocryptine, a dopamine agonist: a clinical trial. | 2001 May 1 |
|
[Reversible blindness caused by an invasive prolactinoma]. | 2001 May 25 |
|
[Cerebral meningeal hemorrhage and acute cerebral angiopathy associated with the taking of phenylpropanolamine: a new case]. | 2001 May-Jun |
|
Sleep attacks and antiparkinsonian drugs: a pilot prospective pharmacoepidemiologic study. | 2001 May-Jun |
|
Dopamine D(2) receptor activation causes mitogenesis via p44/42 mitogen-activated protein kinase in opossum kidney cells. | 2001 Sep |
|
Clinical management of neuroleptic malignant syndrome. | 2001 Winter |
Sample Use Guides
Type 2 diabetes mellitus: Initial dose is one tablet (0.8 mg) daily increased weekly by one tablet until maximal tolerated daily dose of 1.6 to 4.8 mg is achieved.
Hyperprolactinemic Indications: The initial dosage in adults is ½ to one 2½ mg scored tablet daily. An additional 2½ mg tablet may be added to the treatment regimen as tolerated every 2-7 days until an optimal therapeutic response is achieved. The therapeutic dosage ranged from 2.5-15 mg daily in adults studied clinically.
Parkinson’s Disease: The initial dose is ½ of a 2½ mg twice daily with meals. Assessments are advised at 2-week intervals during dosage titration to ensure that the lowest
dosage producing an optimal therapeutic response is not exceeded. If necessary, the dosage may be increased every 14-28 days by 2½ mg/day with meals.
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/20599932
Bromocriptine has been shown to augment glutamate uptake at a concentration of 10 uM in HeLaS3 cells that stably express EAAT1, the human homolog of GLAST. Therefore, it was evaluated whether bromocriptine affects D-[3 H]aspartate uptake in HEK293/EcR cells expressing EAAT2. However, bromocriptine failed to alter D-[3 H]aspartate uptake at concentrations as high as 30 uM, suggesting that bromocriptine has little or no effect on the excitatory amino acid uptake via EAAT2.
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
LIVERTOX |
123
Created by
admin on Sat Jun 26 06:09:41 UTC 2021 , Edited by admin on Sat Jun 26 06:09:41 UTC 2021
|
||
|
NDF-RT |
N0000175827
Created by
admin on Sat Jun 26 06:09:41 UTC 2021 , Edited by admin on Sat Jun 26 06:09:41 UTC 2021
|
||
|
WHO-ATC |
N04BC01
Created by
admin on Sat Jun 26 06:09:41 UTC 2021 , Edited by admin on Sat Jun 26 06:09:41 UTC 2021
|
||
|
NDF-RT |
N0000007618
Created by
admin on Sat Jun 26 06:09:41 UTC 2021 , Edited by admin on Sat Jun 26 06:09:41 UTC 2021
|
||
|
NDF-RT |
N0000007618
Created by
admin on Sat Jun 26 06:09:41 UTC 2021 , Edited by admin on Sat Jun 26 06:09:41 UTC 2021
|
||
|
NCI_THESAURUS |
C1509
Created by
admin on Sat Jun 26 06:09:41 UTC 2021 , Edited by admin on Sat Jun 26 06:09:41 UTC 2021
|
||
|
WHO-ATC |
G02CB01
Created by
admin on Sat Jun 26 06:09:41 UTC 2021 , Edited by admin on Sat Jun 26 06:09:41 UTC 2021
|
||
|
WHO-VATC |
QG02CB01
Created by
admin on Sat Jun 26 06:09:41 UTC 2021 , Edited by admin on Sat Jun 26 06:09:41 UTC 2021
|
||
|
NCI_THESAURUS |
C66884
Created by
admin on Sat Jun 26 06:09:41 UTC 2021 , Edited by admin on Sat Jun 26 06:09:41 UTC 2021
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
D001971
Created by
admin on Sat Jun 26 06:09:41 UTC 2021 , Edited by admin on Sat Jun 26 06:09:41 UTC 2021
|
PRIMARY | |||
|
25614-03-3
Created by
admin on Sat Jun 26 06:09:41 UTC 2021 , Edited by admin on Sat Jun 26 06:09:41 UTC 2021
|
PRIMARY | |||
|
35
Created by
admin on Sat Jun 26 06:09:41 UTC 2021 , Edited by admin on Sat Jun 26 06:09:41 UTC 2021
|
PRIMARY | |||
|
3A64E3G5ZO
Created by
admin on Sat Jun 26 06:09:41 UTC 2021 , Edited by admin on Sat Jun 26 06:09:41 UTC 2021
|
PRIMARY | |||
|
31101
Created by
admin on Sat Jun 26 06:09:41 UTC 2021 , Edited by admin on Sat Jun 26 06:09:41 UTC 2021
|
PRIMARY | |||
|
247-128-5
Created by
admin on Sat Jun 26 06:09:41 UTC 2021 , Edited by admin on Sat Jun 26 06:09:41 UTC 2021
|
PRIMARY | |||
|
C62010
Created by
admin on Sat Jun 26 06:09:41 UTC 2021 , Edited by admin on Sat Jun 26 06:09:41 UTC 2021
|
PRIMARY | |||
|
SUB05918MIG
Created by
admin on Sat Jun 26 06:09:41 UTC 2021 , Edited by admin on Sat Jun 26 06:09:41 UTC 2021
|
PRIMARY | |||
|
1760
Created by
admin on Sat Jun 26 06:09:41 UTC 2021 , Edited by admin on Sat Jun 26 06:09:41 UTC 2021
|
PRIMARY | RxNorm | ||
|
BROMOCRIPTINE
Created by
admin on Sat Jun 26 06:09:41 UTC 2021 , Edited by admin on Sat Jun 26 06:09:41 UTC 2021
|
PRIMARY | |||
|
3365
Created by
admin on Sat Jun 26 06:09:41 UTC 2021 , Edited by admin on Sat Jun 26 06:09:41 UTC 2021
|
PRIMARY | |||
|
25614-03-3
Created by
admin on Sat Jun 26 06:09:41 UTC 2021 , Edited by admin on Sat Jun 26 06:09:41 UTC 2021
|
PRIMARY | |||
|
CHEMBL493
Created by
admin on Sat Jun 26 06:09:41 UTC 2021 , Edited by admin on Sat Jun 26 06:09:41 UTC 2021
|
PRIMARY | |||
|
DB01200
Created by
admin on Sat Jun 26 06:09:41 UTC 2021 , Edited by admin on Sat Jun 26 06:09:41 UTC 2021
|
PRIMARY | |||
|
M2694
Created by
admin on Sat Jun 26 06:09:41 UTC 2021 , Edited by admin on Sat Jun 26 06:09:41 UTC 2021
|
PRIMARY | Merck Index | ||
|
Bromocriptine
Created by
admin on Sat Jun 26 06:09:41 UTC 2021 , Edited by admin on Sat Jun 26 06:09:41 UTC 2021
|
PRIMARY | |||
|
403
Created by
admin on Sat Jun 26 06:09:41 UTC 2021 , Edited by admin on Sat Jun 26 06:09:41 UTC 2021
|
PRIMARY |
ACTIVE MOIETY
SALT/SOLVATE (PARENT)